22 results
DEF 14C
BGLC
BioNexus Gene Lab Corp
29 Feb 24
Information statement
5:16pm
of the audit work, any restrictions on the scope of activities or access to requested information, and any significant disagreements with management.
9. Review
PRE 14C
BGLC
BioNexus Gene Lab Corp
26 Jan 24
Preliminary information
4:05pm
of the audit work, any restrictions on the scope of activities or access to requested information, and any significant disagreements with management.
9
8-K
EX-1.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific … by the Company, on the one hand, or the Underwriter, on the other hand, and the parties’ relative intent, knowledge, access to information
424B4
BGLC
BioNexus Gene Lab Corp
21 Jul 23
Prospectus supplement with pricing info
3:37pm
biopsies are performed on peripheral blood, which is easy to access, it allows for more widespread use, particularly in patients who cannot have surgery … liquidity or when BioNexus’ securities cannot be sold at attractive prices or at all, in which case BioNexus would not be able to access capital from
8-K
EX-10.5
h55 t4iwn6adfnhukm
30 Dec 20
Entry into a Material Definitive Agreement
2:09pm
10-K
ymcs4
31 Mar 20
Annual report
1:12pm